Effect Of Empagliflozin On Blood Pressure In Patients With Type 2 Diabetes Mellitus

Objective:Typical clinical cases were collected,by studying the effect of Empagliflozin on blood pressure in patients with type 2 diabetes,it is proved that Empagliflozin can provide additional cardiovascular clinical advantages for most patients in addition to lowering blood glucose,providing certain evidence for Empagliflozin in lowering blood pressure and providing new ideas for the treatment of hypertension.Methods:In this study,patients with type 2 diabetes and hypertension complicated with type 2 diabetes admitted to our hospital from January 2019 to December 2020 were continuously collected as the research objects.The subjects were given Empagliflozin10 mg and other basic treatment after admission.After a period of treatment,Systolic blood pressure(SBP)and diastolic blood pressure(DBP)before and after treatment were observed and compared.The incidence of adverse reactions(urinary tract infection,hypotension,DKA,etc.)during hospitalization of the subjects was observed,and the data were collected and sorted out.Finally,statistical methods were used to draw conclusions.Outcome:(1)Systolic blood pressure and diastolic blood pressure in patients with type 2diabetes mellitus and hypertension combined with type 2 diabetes mellitus showed a downward trend during the treatment period of Empagliflozin compared with before treatment.Systolic blood pressure in hypertensive patients combined with type 2 diabetes mellitus group and type 2 diabetes mellitus group decreased after 2 weeks of treatment,and the difference between them was statistically significant(P<0.05).There was no significant change in diastolic blood pressure after 2 weeks of treatment in patients with hypertension combined with type 2 diabetes compared with before admission,and a slight decrease in diastolic blood pressure in patients with type 2 diabetes after 2 weeks of treatment,with no statistical significance between the two groups(P<0.05).ABSTRACT(2)In the type 2 diabetes group,the systolic blood pressure of patients before the use of Empagliflozin was higher than that after the use of Empagliflozin,the median difference between the two groups was 6(4-8),the difference was statistically significant(P<0.001);The diastolic blood pressure of patients before Empagliflozin treatment was higher than that afte r Empagliflozin treatment,with a median difference of 3.00(2.00-6.00)between the two groups,which was not statistically significant(P = 0.334).There was no significant change in heart rate between patients before and after Empagliflozin use,and the median difference between the two groups was 1.00(-2-4),the difference was not statistically significant(P >0.05).See Table 3 for details.In the hypertension group combined with type 2 diabetes,systolic blood pressure of patients before the use of Empagliflozin was greater than that after the use of Empagliflozin,the median difference between the two groups was 5(3.00-5.00),the difference was statistically significant(P<0.001);The diastolic blood pressure of patients before Empagliflozin was greater than that after Empagliflozin,with a median difference of 1.00(-0.75-3.00)between the two groups,the difference being statistically significant(P = 0.001).There was no significant change in heart rate between patients before and afte r Empagliflozin use.The median difference between the two groups was 1.00(-2.00-4.00),and the difference was not statistically significant(P >0.05).(3)The median difference in diastolic blood pressure between patients with type 2diabetes mellitus and those with hypertension combined with type 2 diabetes mellitus was 3.0/1.0mm Hg,respectively.Test results P<0.05,there was a difference in diastolic blood pressure between the two groups.The median difference in systolic blood pressure between the two groups was 6.0/5.0mm Hg,and the test results were P<0.05,there was a difference in systolic blood pressure between the two groups.(4)In type 2 diabetes group,there were 6 patients with urinary tract infection,accounting for 7.41%,and 2 patients with ketosis,accounting for 2.47%.The number of patients with hypertension combined with type 2 diabetes had urinary tract infection was 2,accounting for 5.88%,and the number of patients with ketosis was 0,ABSTRACT accounting for 0.00%,and there was no statistical significance between the two groups(P>0.05).There was no hypotension during hospitalization in either group.Conclusion:(1)During the treatment,Empagliflozin can not only reduce blood glucose,but also reduce patients’ systolic and diastolic blood pressure,which has additional cardiovascular advantages.(2)There were no obvious adverse drug reactions during the treatment of Empagliflozin,and the safety was relatively high.